UpcomingPDUFA target action date

Povetacicept

Vertex Pharmaceuticals (VRTX)

Marketer take

Would add another entrant to a fast-growing IgAN market that already includes Trutakna, raising the bar for nephrologist differentiation messaging.

Sponsor company
Vertex Pharmaceuticals (VRTX)
Indication
IgA nephropathy (accelerated approval)
Therapeutic area
Nephrology
Event
PDUFA target action date
Date
Nov 30, 2026
Status
Upcoming
Source
SEC filing
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move